MIMEDX GROUP INC (MDXG) Stock Price, Quote, News and Overview
NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD
MDXG Quote, Performance and Key Statistics
NASDAQ:MDXG (6/4/2025, 10:25:45 AM)
6.4597
-0.02 (-0.31%)
The current stock price of MDXG is 6.4597 USD. In the past month the price decreased by -2.11%. In the past year, price decreased by -7.82%.
MDXG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.44 | 334.50B | ||
| AMGN | AMGEN INC | 14.03 | 156.61B | ||
| GILD | GILEAD SCIENCES INC | 14.29 | 137.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.83B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.18 | 53.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.15B | ||
| ARGX | ARGENX SE - ADR | 101.12 | 35.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.63 | 28.00B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.45B | ||
| NTRA | NATERA INC | N/A | 22.38B | ||
| BIIB | BIOGEN INC | 8.37 | 19.41B | ||
| UTHR | UNITED THERAPEUTICS CORP | 13.16 | 14.88B |
Related stock screener links
About MDXG
Company Profile
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 837 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Company Info
MIMEDX GROUP INC
1775 W Oak Commons Court, Ne
Marietta GEORGIA 30062 US
CEO: Timothy R. Wright
Employees: 895
Phone: 17706519100
MIMEDX GROUP INC / MDXG FAQ
What is the stock price of MIMEDX GROUP INC today?
The current stock price of MDXG is 6.4597 USD. The price decreased by -0.31% in the last trading session.
What is the ticker symbol for MIMEDX GROUP INC stock?
The exchange symbol of MIMEDX GROUP INC is MDXG and it is listed on the Nasdaq exchange.
On which exchange is MDXG stock listed?
MDXG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MIMEDX GROUP INC stock?
11 analysts have analysed MDXG and the average price target is 12.24 USD. This implies a price increase of 89.48% is expected in the next year compared to the current price of 6.4597. Check the MIMEDX GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MIMEDX GROUP INC worth?
MIMEDX GROUP INC (MDXG) has a market capitalization of 954.10M USD. This makes MDXG a Small Cap stock.
How many employees does MIMEDX GROUP INC have?
MIMEDX GROUP INC (MDXG) currently has 895 employees.
What are the support and resistance levels for MIMEDX GROUP INC (MDXG) stock?
MIMEDX GROUP INC (MDXG) has a support level at 6.45 and a resistance level at 6.97. Check the full technical report for a detailed analysis of MDXG support and resistance levels.
Is MIMEDX GROUP INC (MDXG) expected to grow?
The Revenue of MIMEDX GROUP INC (MDXG) is expected to grow by 8.4% in the next year. Check the estimates tab for more information on the MDXG EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MIMEDX GROUP INC (MDXG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDXG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDXG, evaluating the profitability, health, valuation and growth aspects
- MIMEDX GROUP INC (MDXG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MIMEDX GROUP INC (MDXG) Sales and EPS estimates to see what analysts future expectations are.
- MIMEDX GROUP INC (MDXG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MIMEDX GROUP INC (MDXG) Insider and Institutional Ownership to learn about the owners and their transactions.
- MIMEDX GROUP INC (MDXG) Stock Chart to make your own analysis
- MIMEDX GROUP INC (MDXG) Latest news and press-releases to stay up to date.
Does MIMEDX GROUP INC (MDXG) stock pay dividends?
MDXG does not pay a dividend.
When does MIMEDX GROUP INC (MDXG) report earnings?
MIMEDX GROUP INC (MDXG) will report earnings on 2025-07-29, after the market close.
What is the Price/Earnings (PE) ratio of MIMEDX GROUP INC (MDXG)?
The PE ratio for MIMEDX GROUP INC (MDXG) is 23.07. This is based on the reported non-GAAP earnings per share of 0.28 and the current share price of 6.4597 USD. Check the full fundamental report for a full analysis of the valuation metrics for MDXG.
What is the Short Interest ratio of MIMEDX GROUP INC (MDXG) stock?
The outstanding short interest for MIMEDX GROUP INC (MDXG) is 3.69% of its float. Check the ownership tab for more information on the MDXG short interest.
MDXG Technical Analysis
MDXG Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MDXG. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability.
MDXG Financial Highlights
Over the last trailing twelve months MDXG reported a non-GAAP Earnings per Share(EPS) of 0.28. The EPS decreased by -37.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.4% | ||
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| Debt/Equity | 0.09 |
MDXG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to MDXG. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -13.48% and a revenue growth 8.4% for MDXG